TRIAL EXPLORING FEASIBILITY OF DENSIFICATION AND OPTIMAL SEQUENCING OF POSTOPERATIVE ADJUVANT FLUOROURACIL, EPIRUBICIN PLUS CYCLOPHOSPHAMIDE (FEC) AND DOCETAXEL CHEMOTHERAPY IN PATIENTS WITH HIGH RISK PRIMARY OPERABLE BREAST CANCER: